662 reports of this reaction
2.3% of all POLYETHYLENE GLYCOL 400 reports
#6 most reported adverse reaction
CONSTIPATION is the #6 most commonly reported adverse reaction for POLYETHYLENE GLYCOL 400, manufactured by Bausch & Lomb Incorporated. There are 662 FDA adverse event reports linking POLYETHYLENE GLYCOL 400 to CONSTIPATION. This represents approximately 2.3% of all 28,955 adverse event reports for this drug.
Patients taking POLYETHYLENE GLYCOL 400 who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for POLYETHYLENE GLYCOL 400, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for POLYETHYLENE GLYCOL 400:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 662 FDA reports for POLYETHYLENE GLYCOL 400. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 2.3% of all adverse event reports for POLYETHYLENE GLYCOL 400, making it a notable side effect.
If you experience constipation while taking POLYETHYLENE GLYCOL 400, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.